Sugi Predict

Sugi Predict / Targets / PDE6D

PDE6D

Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta · O43924 · PDE6D on Sugi Atlas →

26,563 patent compounds predicted against PDE6D, 19,783 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL198053 SCHEMBL198053 0.56 11/20
SCHEMBL200001 SCHEMBL200001 0.68 10/20
SCHEMBL198351 SCHEMBL198351 0.57 10/20
SCHEMBL197272 SCHEMBL197272 0.52 10/20
SCHEMBL200042 SCHEMBL200042 0.51 9/20
SCHEMBL197838 SCHEMBL197838 0.63 8/20
SCHEMBL198410 SCHEMBL198410 0.56 6/20
SCHEMBL282861 SCHEMBL282861 0.37 6/20
SCHEMBL328547 SCHEMBL328547 0.36 6/20
SCHEMBL283958 SCHEMBL283958 0.36 6/20
SCHEMBL972494 SCHEMBL972494 0.72 5/20
SCHEMBL972096 SCHEMBL972096 0.60 5/20
SCHEMBL197761 SCHEMBL197761 0.53 5/20
SCHEMBL969605 SCHEMBL969605 0.77 4/20
SCHEMBL538508 SCHEMBL538508 0.70 4/20
SCHEMBL538509 SCHEMBL538509 0.70 4/20
SCHEMBL1032 SCHEMBL1032 0.68 4/20
SCHEMBL820557 SCHEMBL820557 0.65 4/20
SCHEMBL518254 SCHEMBL518254 0.64 4/20
SCHEMBL9906 SCHEMBL9906 0.64 4/20

Clinical trials — most relevant to PDE6D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
PDE6A Gene Therapy for Retinitis Pigmentosa PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Promising ROd-cone DYstrophy Gene therapY PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study PHASE2UNKNOWN
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder PHASE2UNKNOWN
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
Effects of Lutein in Retinitis Pigmentosa PHASE1/PHASE2COMPLETED
Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa PHASE1/PHASE2RECRUITING
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults PHASE1COMPLETED
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Prospective Natural History Study of Retinitis Pigmentosa nanACTIVE_NOT_RECRUITING
Retrospective Natural History Study of Retinitis Pigmentosa nanUNKNOWN
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM) nanWITHDRAWN
RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa nanWITHDRAWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants nanRECRUITING
Is Pentoxifylline Able to Improve Olfactory Sensitivity? nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE6D binder may also engage these)

ProteinNameSimilarity
Q9XT54 — 1.000 Q9XT54 →
O55057 — 1.000 O55057 →
Q95142 — 1.000 Q95142 →
B4Q785 — 1.000 B4Q785 →
B4HYQ2 — 1.000 B4HYQ2 →
B4LSE6 — 1.000 B4LSE6 →
B0WS18 — 1.000 B0WS18 →
Q9VLJ0 — 1.000 Q9VLJ0 →
B4NXG9 — 1.000 B4NXG9 →
B4GJ61 — 1.000 B4GJ61 →
B3N7D5 — 1.000 B3N7D5 →
B4JDZ5 — 1.000 B4JDZ5 →
Q18268 — 1.000 Q18268 →
Q17FF6 — 0.997 Q17FF6 →
B4KG03 — 0.996 B4KG03 →
Q29JT7 — 0.996 Q29JT7 →
B4N7S9 — 0.995 B4N7S9 →
Q7PZ66 — 0.994 Q7PZ66 →
Q66JA9 — 0.994 Q66JA9 →
Q6INE2 — 0.994 Q6INE2 →
Q614K9 — 0.993 Q614K9 →
Q23652 — 0.992 Q23652 →
Q9XWP6 — 0.992 Q9XWP6 →
Q9CQA8 — 0.992 Q9CQA8 →
Q4PBU8 — 0.991 Q4PBU8 →
Q54N45 — 0.991 Q54N45 →
Q10111 — 0.990 Q10111 →
Q6PS57 — 0.990 Q6PS57 →
Q18008 — 0.990 Q18008 →
Q7R7U6 — 0.990 Q7R7U6 →